Uncategorized
Allergan, Editas Medicine enter research and development agreement
Allergan and Editas Medicine have entered into a strategic research and development alliance, according to a joint press release from the companies.The agreement will give Allergan exclusive access and the option to license up to five of Editas’ genome-editing ocular programs, including Leber congenital amaurosis (LCA10).